World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
90
Citations
43959
World Ranking
11986
National Ranking
648

Ralf Gutzmer publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Ralf Gutzmer sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 543 publications — 65th percentile

65% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Ralf Gutzmer D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Ralf Gutzmer sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 90 D-Index — 41st percentile

41% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Ralf Gutzmer is affiliated with Hannover Medical School in Germany. Their research primarily focuses on medicine, with a substantial number of publications in oncology and related biomedical fields.

The main fields of study for their work include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Within these fields, the more specific subfields of study that characterize their research are:

  • Oncology
  • Molecular Biology
  • Dermatology
  • Epidemiology
  • Immunology

The major topics addressed in their work encompass:

  • Cutaneous Melanoma Detection and Management
  • Cancer Immunotherapy and Biomarkers
  • Melanoma and MAPK Pathways
  • CAR-T cell therapy research
  • Nonmelanoma Skin Cancer Studies
  • Immunotherapy and Immune Responses
  • Cutaneous lymphoproliferative disorders research

Ralf Gutzmer has contributed to several recent papers, notably including:

  • Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial, 2020, The Lancet

Their frequent coauthors reflect ongoing collaborations in the field and include:

  • Dirk Schadendorf
  • Carmen Loquai
  • Friedegund Meier
  • Selma Ugurel
  • Jessica C. Hassel

Scientific contributions by Ralf Gutzmer have been published frequently in several journals, highlighting the venues they often publish in:

  • European Journal of Cancer
  • JDDG Journal der Deutschen Dermatologischen Gesellschaft
  • Journal of Clinical Oncology
  • Annals of Oncology
  • Cancers

Best Publications

  • Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

    Axel Hauschild;Jean Jacques Grob;Lev V. Demidov;Thomas Jouary

  • Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

    Eliezer M. Van Allen;Eliezer M. Van Allen;Diana Miao;Diana Miao;Bastian Schilling;Sachet A. Shukla;Sachet A. Shukla

  • Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

    Jeffrey S Weber;Sandra P D'Angelo;David Minor;F Stephen Hodi

  • Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

    Alexander M.M. Eggermont;Christian U. Blank;Mario Mandala;Georgina V. Long

  • Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

    David Liu;David Liu;Bastian Schilling;Bastian Schilling;Derek Liu;Derek Liu;Antje Sucker

  • The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma

    Eliezer M. Van Allen;Eliezer M. Van Allen;Nikhil Wagle;Nikhil Wagle;Antje Sucker;Daniel J. Treacy

  • Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

    Reinhard Dummer;Paolo A Ascierto;Helen J Gogas;Ana Arance

  • Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy.

    Lars Hofmann;Andrea Forschner;Carmen Loquai;Simone M. Goldinger

  • International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors

    Pertti Panula;Paul L. Chazot;Marlon Cowart;Ralf Gutzmer

  • Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

    Reinhard Dummer;Paolo A Ascierto;Helen J Gogas;Ana Arance

  • Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial.

    Ralf Gutzmer;Daniil Stroyakovskiy;Helen Gogas;Caroline Robert

  • Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy.

    Lisa Zimmer;Simone M. Goldinger;Lars Hofmann;Carmen Loquai

  • Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab.

    Benjamin Weide;Alexander Martens;Jessica C. Hassel;Carola Berking

  • Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.

    James Larkin;David Minor;Sandra D'Angelo;Bart Neyns

  • Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

    Paolo A. Ascierto;Michele Del Vecchio;Caroline Robert;Andrzej Mackiewicz

  • The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network

    Caroline J. Voskens;Simone M. Goldinger;Carmen Loquai;Caroline Robert

  • Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial

    Reinhard Dummer;Dirk Schadendorf;Paolo A Ascierto;Ana Arance

  • Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial

    Michael R. Migden;Alexander Guminski;Ralf Gutzmer;Luc Dirix

  • Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy

    Thomas K. Eigentler;Jessica C. Hassel;Carola Berking;Jens Aberle

  • Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

    David Liu;Bastian Schilling;Derek Liu;Antje Sucker

Frequent Co-Authors

Dirk Schadendorf
Dirk Schadendorf University of Duisburg-Essen
Alexander Kapp
Alexander Kapp Hannover Medical School
Claus Garbe
Claus Garbe University of Tübingen
Thomas Werfel
Thomas Werfel Hannover Medical School
Axel Hauschild
Axel Hauschild Kiel University
Carola Berking
Carola Berking Ludwig-Maximilians-Universität München
Reinhard Dummer
Reinhard Dummer University of Zurich
Paolo A. Ascierto
Paolo A. Ascierto National Institutes of Health
Jochen Utikal
Jochen Utikal German Cancer Research Center
Caroline Robert
Caroline Robert University of Paris-Saclay

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Interested in a career in Medicine, but considering alternative or complementary healthcare paths? There are various online degree programs in the health sector that offer flexibility, affordability, and strong career prospects.

For those who aspire to leadership roles in healthcare settings, pursuing a most affordable mha programs (Master’s in Healthcare Administration) can open doors to management positions in hospitals, clinics, and allied healthcare organizations.

Nurses aiming to advance their clinical expertise may consider most affordable dnp programs (Doctor of Nursing Practice), which emphasize leadership, policy, and evidence-based practice.

If pharmacy sparks your interest, you can now complete much of your training through pharmacy degree online programs, preparing you for pharmaceutical care and research roles.

For those more inclined toward the data and technology side of healthcare, exploring rhit programs online (Registered Health Information Technician) can lead to careers in managing patient data, compliance, and information security.

These online programs provide diverse pathways for making a meaningful impact in healthcare, often at a lower cost and greater convenience compared to traditional on-campus degrees.

Best Scientists Citing Ralf Gutzmer

Trending Scientists

Recently Published Articles